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BACKGROUND: High BCAR4 and ERBB2 mRNA levels in primary breast cancer associate with tamoxifen resistance and poor patient
outcome. We determined whether BCAR4 expression sensitises breast cancer cells to lapatinib, and identifies a subgroup of patients
who possibly may benefit from ERBB2-targeted therapies despite having tumours with low ERBB2 expression.
METHODS: Proliferation assays were applied to determine the effect of BCAR4 expression on lapatinib treatment. Changes in cell
signalling were quantified with reverse-phase protein microarrays. Quantitative reverse-transcriptase polymerase chain reaction
(RT–PCR) of ERBB2 and BCAR4 was performed in 1418 primary breast cancers. Combined BCAR4 and ERBB2 mRNA levels were
evaluated for association with progression-free survival (PFS) in 293 oestrogen receptor-a (ER)-positive patients receiving tamoxifen
as first-line monotherapy for recurrent disease.
RESULTS: BCAR4 expression strongly sensitised ZR-75-1 and MCF7 breast cancer cells to the combination of lapatinib and
antioestrogens. Lapatinib interfered with phosphorylation of ERBB2 and its downstream mediators AKT, FAK, SHC, STAT5, and
STAT6. Reverse transcriptase–PCR analysis showed that 27.6% of the breast cancers were positive for BCAR4 and 22% expressed
also low levels of ERBB2. The clinical significance of combining BCAR4 and ERBB2 mRNA status was underscored by the finding that
the group of patients having BCAR4-positive/ERBB2-low-expressing cancers had a shorter PFS on tamoxifen treatment than the
BCAR4-negative group.
CONCLUSION: This study shows that BCAR4 expression identifies a subgroup of ER-positive breast cancer patients without
overexpression of ERBB2 who have a poor outcome and might benefit from combined ERBB2-targeted and antioestrogen therapy.
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Tamoxifen has an important role in the treatment of patients with
oestrogen receptor-a (ER)-positive primary breast cancer, both in
the adjuvant and metastatic setting (Davies et al, 2011). Its efficacy
is limited by primary (intrinsic) or secondary (acquired)
resistance. A better understanding of the mechanisms involved is
required to overcome resistance and for developing more effective
therapies. Several genes and mechanism causing antioestrogen
resistance were identified (Dorssers and Veldscholte, 1997; Van
Agthoven et al, 1998; Brinkman et al, 2000; Massarweh and Schiff,
2007; Riggins et al, 2007; Musgrove and Sutherland, 2009; Barone
et al, 2010; Van Agthoven et al, 2010), including the novel breast
cancer antioestrogen resistance 4 (BCAR4) gene (Meijer et al,
2006). Ectopic expression of BCAR4 causes antioestrogen resis-
tance, anchorage independence, and tumour growth in nude mice
(Meijer et al, 2006; Godinho et al, 2011). BCAR4 mRNA is detected
in 22–29% of primary breast cancers. High levels are associated
with shorter progression-free survival (PFS) in patients treated
with tamoxifen for recurrent disease, and associate with poor
metastasis-free survival (MFS) and overall survival (OS), reflecting
tumour aggressiveness (Godinho et al, 2010).
BCAR4 has been found in several mammalian species, being well
conserved in higher primates (Meijer et al, 2006; Godinho et al,
2011). In the functional screening for genes causing tamoxifen
resistance, it was isolated from a human placenta cDNA library
only (Meijer et al, 2006; Godinho et al, 2011). Searches in public
expression databases and in the literature showed that high BCAR4
expression is only found in placenta and the oocyte (Meijer et al,
2006; Godinho et al, 2011). In other normal adult tissues,
expression of BCAR4 was not found. The species and tissue-
specific expression strongly indicates a role for BCAR4 in
mammalian early development and pregnancy. Surprisingly, the
BCAR4 gene is absent in the mouse and rat (Godinho et al, 2011).
Important differences exist between human and mouse placental
development and function. In the mouse, in contrast to the human
situation, trophoblast implantation is superficial, the transforma-
tion of the uterine arteries depends on maternal factors, and
mouse placenta produces fewer placental hormones (Malassine
et al, 2003; Carter, 2007). At this point it is only possible to
speculate on the function of this gene, but it is likely that
differences in placental development and function could explain the
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absence in these organisms. BCAR4 may have a function in placenta
and early development, therefore it cannot be excluded that in mouse
and rat its function has been taken over by other genes.
BCAR4-induced tamoxifen resistance depends on the presence
of ERBB2 (HER2) and ERBB3 receptors (Godinho et al, 2010). We
hypothesised that BCAR4 expression may sensitise breast cancer
cells to the small-molecule tyrosine kinase activity inhibitor of
EGFR and ERBB2. In this study, BCAR4-expressing cells were
assessed for their sensitivity to lapatinib, given alone and
in combination with antioestrogens. In addition, the effects of
treatment on ERBB2 and ERBB3 downstream signalling were
measured. As increased ERBB2 activity has been associated with
resistance to cytotoxic agents in breast cancer, the impact of
BCAR4 expression on sensitivity to several cytotoxic drugs was
assessed. The results of our cell line studies showed that ectopic
expression of BCAR4 results in activation of the ERBB2 signalling
pathway without overexpression of ERBB2. Therefore, we deter-
mined the incidence of breast cancers expressing BCAR4 and low
ERBB2 levels, and how this group of patients fares when treated
with tamoxifen for advanced disease.
MATERIALS AND METHODS
Cell lines and culture conditions
ZR-75-1 and MCF7 cell lines were kind gifts of RJB King (ICRF,
London) and RB Dickson (NCI, Bethesda), respectively. Cell lines
were initially authenticated by karyotyping, and in November 2011
using the AmpFlSTR Identifiler Direct PCR Amplification Kit
(Applied Biosystems International, Nieuwerkerk a/d Ijssel, The
Netherlands). Cell lines derived from the breast cancer cell line
ZR-75-1 containing empty vector, or expression constructs with
BCAR4 (Meijer et al, 2006), BCAR1 (Brinkman et al, 2000), BCAR3
(Van Agthoven et al, 1998), or EGFR (Van Agthoven et al, 1992),
and MCF7 breast cancer cells with a construct containing BCAR4
were cultured as previously described (Van Agthoven et al, 1998).
Drug sensitivity assays
Cells were seeded in 96-well plates at a density of 5000 cells per well
in 100 ml RPMI 1640 medium (Invitrogen, Breda, The Nether-
lands). After 24 h, serial dilutions of lapatinib (GlaxoSmithKline,
Stevenage, UK), doxorubicin (Pharmachemie B.V., Haarlem, The
Netherlands), 5-fluorouracil (EBEWE Pharma, Unterach, Austria),
methotrexate (Emthexate PF, Pharmachemie B.V.), ifosfamide
(Holoxan, Baxter B.V., Utrecht, The Netherlands), or paclitaxel
(Paclitaxel, EBEWE Pharma) were added. All drugs were tested in
combination with 17 b-oestradiol or 4-hydroxytamoxifen (Sigma-
Aldrich Chemie, Zwijndrecht, the Netherlands) or ICI182,780
(Zeneca Pharmaceuticals, Macclesfield, UK). To assay the effects of
oestrogen, cells were seeded at a density of 5000 cells per well in
100ml RPMI 1640 without phenol red, supplemented with 6% heat-
inactivated bovine calf serum (Hyclone, Logan, UT, USA). Twenty-
four hours after seeding, 100ml of medium containing 0.01, 0.1, or
1 mM lapatinib and increasing concentrations of oestradiol were
added. WST-1 proliferation assays (Roche Diagnostics, Almere,
The Netherlands) were performed on ZR-75-1- or MCF7-derived
cell lines after 5 or 6 days, respectively. IC50 values were estimated
by sigmoid inhibitory effect models 107 and 108 as implemented in
the software programme Phoenix WinNonLin 6.1 (Pharsight,
Mountain View, CA, USA).
Inhibition of gene expression by small interfering
(si)RNAs
Transfections with HiPerfect (Qiagen, Venlo, The Netherlands)
were performed according to the manufacturer’s instructions.
Small interfering RNAs were On TARGETplus-SMARTpools, each
consisting of three different oligonucleotides: EGFR (L-003114-00-
0005), ERBB2 (L-003126-00-005), ERBB3 (L-003127-00-0005), and
ERBB4 (L003128-00-0005; Dharmacon, Perbio-Science, Etten Leur,
The Netherlands). Final concentration of siRNA was 5 nM. WST-1
assays were performed after 6 days.
Reverse-phase protein microarrays
Cells cultured in oestradiol- or 4-hydroxytamoxifen-containing
medium were treated without or with 0.01 or 0.1 mM lapatinib for
17 h. Cells were rinsed with ice-cold DPBS (Gibco, Invitrogen), and
lysed with pre-heated (75 1C) extraction buffer consisting of equal
parts of T-PER (Pierce, Thermo Scientific, Etten-Leur, The
Netherlands) and Tris-Glycine-SDS Sample Buffer (Invitrogen)
containing PhosSTOP Phosphatase Inhibitors, Complete Mini
Protease Inhibitors (Roche Diagnostics), and 4% of b-mercap-
toethanol (Merck, Schiphol-Rijk, The Netherlands). Lysates were
boiled for 8min and stored at  80 1C. Reverse-phase protein
microarray analysis was performed as described (Van Agthoven
et al, 2012). A list of antibodies used is presented in Supplementary
Table 1.
Patient samples
ERBB2 and BCAR4 mRNA levels were measured in 1418
ER-positive and negative primary breast cancers as described in
Van Agthoven et al (2009) and Godinho et al (2010). Here we
assessed the prognostic and predictive values of a combined
BCAR4 and ERBB2 status. BCAR4 and ERBB2 were determined
according to the definitions/cut points in the aforementioned
studies. To determine the association of the combination of BCAR4
and ERBB2 mRNA levels and PFS, 293 samples from patients with
ER-positive cancers who received tamoxifen treatment as first-line
therapy for metastatic disease were analysed. The associations of
the combined BCAR4 and ERBB2 levels with tumour aggressive-
ness in terms of MFS and OS were determined on 497 ER-positive
cancers from patients with lymph node–negative disease. None
received systemic adjuvant therapy. Statistical analyses were
performed as previously detailed (Godinho et al, 2010).
Quantification of gene expression
RNA isolation of cell lines, complementary DNA synthesis,
normalisation to reference genes and quantification were per-
formed as described (Sieuwerts et al, 2005; Van Agthoven et al,
2009; Godinho et al, 2010). TaqMan gene expression assays for
EGFR-Hs01076091_m1, ERBB2-Hs00170433_m1, ERBB3-
Hs00176538_m1, ERBB4-Hs00171783_m1, and BCAR4-
Hs00415922_m1 were used according the recommendations of
the supplier Applied Biosystems International.
RESULTS
Inhibition of ERBB2/3 expression abrogates BCAR4-
induced antioestrogen-resistant proliferation
Previously we have shown that BCAR4-induced tamoxifen-
resistant proliferation of ZR-75-1 cells depends on the presence
of ERBB2 and ERBB3 (Godinho et al, 2010), while ERBB2 is not
overexpressed or amplified in this cell line (Hollestelle et al, 2010).
In MCF7 cells, we investigated whether BCAR4 expression also
induces ERBB2/3-mediated proliferation. The expression of the
four ERBB receptors were inhibited with siRNAs, in the absence or
presence of the pure antioestrogen ICI182,780. In contrast to
4-hydroxytamoxifen, this antioestrogen fully inhibits growth of
wild-type MCF7 cells. Inhibition of mRNA transcripts was verified
by quantitative real-time reverse transcriptase polymerase chain
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reaction (RT–PCR, and was more than 70% for EGFR, 88% for
ERBB2, 66% for ERBB3, and 75% for ERBB4.
In foetal bovine serum-containing medium, the proliferation
capacity of MCF7 cells expressing BCAR4 (MCF7/BCAR4) and
MCF7 vector-containing cells was not affected by the inhibition of
the expression of the ERBB receptors (Figure 1A and B). Similarly
to BCAR4 expression in ZR-75-1 cells, MCF7/BCAR4 cells were
antioestrogen resistant and able to grow in the presence of
ICI182,780 (Figure 1A). Under this culture condition, the
inhibition of ERBB2, ERBB3, and ERBB4 expression resulted in
decreased cell proliferation, indicating that also in MCF7/BCAR4
cells, ERBB signalling is involved in antioestrogen resistance.
Growth of MCF7/vector cells was fully inhibited by ICI182,780, and
inhibition of the ERBB receptor expression had no further effect
(Figure 1B).
BCAR4 expression increases the sensitivity of cells
to lapatinib
We speculated that BCAR4 expression may increase the sensitivity
to the EGFR/ERBB2 tyrosine kinase inhibitor lapatinib. Sensitivity
to lapatinib was determined in ZR-75-1 cells containing empty
expression vector (ZR/vector) or BCAR4 (ZR/BCAR4). Cells
expressing BCAR1 (ZR/BCAR1), BCAR3 (ZR/BCAR3), or EGFR
(ZR/EGFR) were used for comparison. These latter genes were
shown to induce tamoxifen resistance by mechanisms independent
of ERBB2 and ERBB3 (Van Agthoven et al, 1992, 1998; Brinkman
et al, 2000; Meijer et al, 2006). Titration experiments showed that
cells expressing BCAR4 were the most sensitive to lapatinib in the
presence of oestradiol (Figure 2A). The IC50 values for ZR/BCAR4
cells were 10- to 20-times lower than the IC50 determined for the
other cell lines. In the presence of oestradiol and lapatinib
expression of BCAR1, BCAR3, or EGFR had no impact on
proliferation, which was similar to the empty vector-containing
cells.
Lapatinib sensitivity was also determined in MCF7 cells. In the
presence of fetal bovine serum alone, the determined IC50 values
for MCF7/BCAR4 cells were similar to the IC50 values determined
for MCF/vector cells (7–9 mM and 8–12mM, respectively). This is in
agreement with the inhibition of the ERBB receptors having no
effect on proliferation of MCF7/BCAR4 under this culture
condition (Figure 1). Under these culture conditions, the cells
apparently depend on the ER pathway for proliferation.
Antioestrogens enhance the sensitivity of BCAR4-
expressing cells to lapatinib
We tested whether antioestrogens could enhance the sensitivity to
lapatinib. Proliferation of wild-type ZR-75-1 cells is fully inhibited
by 1 mM 4-hydroxytamoxifen in the culture medium. ZR/BCAR4
was also the most sensitive cell line to the combination of lapatinib
and 4-hydroxytamoxifen compared with ZR/BCAR1, ZR/BCAR3,
or ZR/EGFR cells (Figure 2B). Tamoxifen further increased
the sensitivity of ZR/BCAR4 cells to lapatinib by approximately
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Figure 1 Knockdown of ERBB receptors reduces proliferation of
antioestrogen-resistant MCF7/BCAR4 cells. MCF7/BCAR4 (A) and
MCF7/vector (B) cells were cultured in the absence (open bars) or
presence (closed bars) of the antioestrogen ICI182,780. The inhibition of
ERBB receptors by specific siRNAs was measured with a proliferation assay.
Average of five replicates and SDs are shown. Significance was determined
by the Mann–Whitney U-test. *Po0.05, compared with cells cultured
without siRNAs. Abbreviation: AU¼ arbitrary units.
0
20
0.0001 0.001 0.01 0.1
Lapatinib (M)
1 10 100
0.0001 0.001 0.01 0.1
Lapatinib (M)
1 10 100
40
R
el
at
iv
e 
gr
ow
th
 (%
)
60
80
100
0
20
40
R
el
at
iv
e 
gr
ow
th
 (%
)
60
80
100
Figure 2 BCAR4 sensitises ZR-75-1 cells to lapatinib. ZR/vector control
(m), ZR/BCAR4 (J), ZR/BCAR1 (B), ZR/BCAR3 (D) or ZR/EGFR cells
(&) were plated in oestradiol-containing medium (A), or 4-hydroxyta-
moxifen-containing medium (B) with increasing doses of lapatinib as
indicated. Concentrations of lapatinib (X axis) are presented on a
logarithmic scale. Results are expressed as a percentage of maximal
growth as measured with a WST-1 proliferation assay. Average of five
replicates and SDs are presented.
BCAR4 sensitises breast cancer cells to lapatinib
MFE Godinho et al
949
& 2012 Cancer Research UK British Journal of Cancer (2012) 107(6), 947 – 955
C
li
n
ic
a
l
S
tu
d
ie
s
three-fold. A very similar lapatinib dose–response curve was
obtained with the presence of ICI182,780 (data not shown).
ZR-75-1 cells with forced expression of the EGFR are tamoxifen
resistant and oestrogen-independent in the presence of 10 ng/ml of
EGF (Van Agthoven et al, 1992). Compared with oestradiol-
stimulated cultures, ZR/EGFR cells were six-fold more sensitive
than controls to the combination of lapatinib, 4-hydroxytamox-
ifen, and EGF. ZR/BCAR1 and ZR/BCAR3 cells showed similar
lapatinib dose–response curves in oestradiol and 4-hydroxyta-
moxifen-containing medium, approximately 35-fold less sensitive
than ZR/BCAR4 cells. Growth of ZR/vector cells was fully inhibited
by 4-hydroxytamoxifen, therefore the sensitivity to lapatinib under
this culture condition is not informative (data not shown).
ICI182,780 increased the sensitivity of MCF7/BCAR4 cells to
lapatinib by approximately 10-fold.
Lapatinib inhibits ERBB2 signalling in BCAR4-expressing
cells
Reverse-phase protein microarray analysis was used to determine
the effects of lapatinib treatment on the levels of 68 total or
phosphorylated proteins having a role in survival, motility, death,
growth, metabolism, and inflammation (Supplementary Table 2).
To circumvent the problem that changes in phosphorylation were
solely due to toxicity, cells were cultured in medium without
lapatinib or with low doses of 0.01 or 0.1 mM lapatinib for 17 h.
These concentrations resulted in limited growth inhibition after 5
days in culture (Figure 2A and B). Lapatinib treatment had no
prominent effects on protein phosphorylation in ZR/vector, ZR/
BCAR1, ZR/BCAR3, or ZR/EGFR cells, while clear changes were
observed for ZR/BCAR4 cells (Figure 3A). We quantified the effects
on the phosphorylation of its target, the ERBB2 receptor, the
ERBB3 receptor, and several downstream mediators. ZR/BCAR4
cells do not express EGFR (Van Agthoven et al, 2012), therefore
changes caused by the addition of lapatinib cannot be attributed to
this pathway.
As observed before (Van Agthoven et al, 2012) in oestradiol-
containing medium, phosphorylation of ERBB2 (Tyr1248) was
12-fold higher in ZR/BCAR4 cells compared with the phosphor-
ylation levels in control cells (Figure 3B). Under this culture
condition, 0.01mM lapatinib completely inhibited ERBB2 phos-
phorylation. The combination of 4-hydroxytamoxifen and 0.1mM
lapatinib resulted in a two-fold decrease in ERBB2 phosphoryla-
tion (Figure 3B). Lapatinib exerted no effect on ERBB2 phosphor-
ylation in the other cell lines.
ZR/BCAR4 cells showed the highest levels of phosphorylated
ERBB3 (Tyr1289; Figure 3C; Van Agthoven et al, 2012). Lapatinib
treatment in oestradiol-containing cultures resulted in moderately
decreased ERBB3 phosphorylation, but had no effect in the
presence of 4-hydroxytamoxifen. In the other cell lines, lapatinib
did not modulate ERBB3 phosphorylation (Figure 3C). Phosphor-
ylation of several downstream mediators, such as AKT (Ser473),
FAK (Tyr576-577), SHC (Tyr317), STAT5 (Tyr694), and STAT6
(Tyr349), was higher in ZR/BCAR4 cells compared with control
cell lines (Figure 3D–H). Similar to the effect on ERBB2
phosphorylation, in oestradiol-containing medium, 0.01mM lapa-
tinib inhibited phosphorylation of these downstream mediators. In
medium containing 4-hydroxytamoxifen, a higher dose of
lapatinib was needed to reduce phosphorylation levels. In the
remaining cell lines, lapatinib treatment had little or no effect on
the phosphorylation of these signalling molecules.
BCAR4-expressing cells alternate between signalling
pathways to survive
Proliferation of ZR/BCAR4 cells was more sensitive to the
combination of lapatinib and 4-hydroxytamoxifen than to the
combination of lapatinib and oestradiol (Figure 2). Moreover,
phosphorylation of ERBB2 and downstream targets is inhibited in
the presence of oestradiol and lapatinib. The addition of
4-hydroxytamoxifen increased ERBB2 levels and downstream
signalling. Therefore, we hypothesised that if the ERBB2 signalling
pathway is inhibited by lapatinib, BCAR4-expressing cells may
switch to the ER pathway to sustain survival and proliferation. To
test this, we analysed the effects of lapatinib treatment on
oestradiol dependence in short-term cultures. While ZR/BCAR4
cells showed maximal proliferation capacity in the absence of
oestradiol (Figure 4A), ZR/vector cells required supplementation
of 10–100 pM of oestradiol. Figure 4B shows that in the presence of
0.01 or 0.1 mM lapatinib, oestrogen dependence of ZR/vector cells
remained unchanged. In contrast, proliferation of ZR/BCAR4 cells
was less inhibited by lapatinib in the presence of more than 10 pM
of oestradiol (Figure 4A). These results indicate that ZR/BCAR4
cells can evade the growth inhibitory effects of lapatinib in part
through ER signalling.
BCAR4 and chemotherapy
As several studies indicate an association between ERBB2
overexpression and resistance to chemotherapy (reviewed in Tan
and Yu, 2007), and BCAR4 expression enhances ERBB2 signalling,
we determined the sensitivity of BCAR4-expressing cells to drugs
currently included in common breast cancer treatment regimens.
To investigate alterations in drug sensitivity, cells were cultured in
oestradiol- or 4-hydroxytamoxifen-containing medium and
increasing concentrations of the different chemotherapeutics.
As a typical example, a dose–response curve of ZR/vector,
ZR/BCAR4, ZR/BCAR1, ZR/BCAR3, and ZR/EGFR cells to
methotrexate is shown in Supplementary Figure S1. No major
differences in sensitivity to the drug between the different cell
lines, either in the presence of oestradiol (Supplementary Figure
S2A) or 4-hydroxytamoxifen (Supplementary Figure S2B), were
observed. Similar results were obtained for ifosfamide,
5-fluorouracil, doxorubicin, and paclitaxel, indicating no changes
in sensitivity of conventional drugs due to the expression of
BCAR4. Moreover, no major differences were found between the
IC50 values determined for all the BCAR cell lines and for the
control cells (Supplementary Table 3), with exception of ZR/
BCAR1 cells being less sensitive to doxorubicin, and ZR/EGFR cells
being less sensitive to doxorubicin and 5-fluorouracil.
BCAR4 mRNA levels may define a subgroup of patients
who are eligible for treatment with established ERBB2
inhibitors
At present, only patients with breast cancers overexpressing
ERBB2 or with gene amplification are eligible for ERBB2-targeted
therapies. Our functional in vitro studies show that BCAR4
activates the ERBB2 pathway yielding resistance against anti-
oestrogens in cell lines not overexpressing ERBB2. This could
imply that BCAR4 expression identifies an additional subgroup of
patients with activated ERBB2, but lacking ERBB2 overexpression.
To investigate the prevalence of this group, both BCAR4 and
ERBB2 mRNA status were determined in a large cohort of primary
breast cancers previously measured by RT–PCR (Van Agthoven
et al, 2009; Godinho et al, 2010). BCAR4 was detected in 392 out of
1418 (27.6%) samples (Figure 5A). High expression of ERBB2 was
detected in 233 specimens (16.4%). Among the BCAR4-positive
samples, 80 had high and 312 had low expression of ERBB2,
indicating the existence of a group of patients (22%) with BCAR4-
positive cancers and low expression of ERBB2.
Clinical relevance of combined BCAR4 and ERBB2 status
BCAR4 and ERBB2 have been found to be independently predictive
for tamoxifen resistance in recurrent breast cancer. While ERBB2
BCAR4 sensitises breast cancer cells to lapatinib
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was not associated with the natural course of the disease in
untreated lymph node–negative ER-positive patients with primary
breast cancer, patients with BCAR4-positive tumours had a shorter
MFS and OS compared with BCAR4-negative tumours (Van
Agthoven et al, 2009; Godinho et al, 2010).
Here we assessed the associations of combined BCAR4 and
ERBB2 status and clinical tamoxifen resistance in recurrent breast
cancer. mRNA levels of 293 ER-positive primary cancers of
patients treated with tamoxifen as first-line therapy for metastatic
disease were analysed for association with the length of PFS. The
individual clinical associations of BCAR4 and ERBB2 mRNA levels
for PFS (Table 1) were in agreement with our previous data (Van
Agthoven et al, 2009; Godinho et al, 2010). Univariate Cox
regression analysis of the combined mRNA status showed that
patients with BCAR4-positive tumours with low levels of ERBB2
had a shorter PFS than patients with BCAR4-negative tumours
with low ERBB2 levels (HR¼ 1.64, P¼ 0.001; Table 1). Patients
with high ERBB2 levels had the shortest PFS, regardless of BCAR4
status (Table 1). The Kaplan–Meier analysis visualises the different
outcomes of the patients stratified according to the combined
BCAR4 and ERBB2 status (Figure 5B). In the multivariate analysis,
the power of the combination of BCAR4 expression and low levels
of ERBB2 was independent of the traditional predictive factors for
PFS (BCAR4-negative/ERBB2-low vs BCAR4-positive/ERBB2-low,
HR¼ 1.50, P¼ 0.011; Table 1).
To assess the associations of combined BCAR4 and ERBB2 levels
and tumour aggressiveness, we analysed mRNA status in 497
primary breast cancers. All patients had ER-positive, lymph node–
negative cancer and did not receive adjuvant systemic therapy,
allowing the analysis of the natural course of the disease. The
mRNA levels were analysed for association with the end points
MFS and OS. Metastasis-free survival in patients with BCAR4-
positive/ERBB2-low tumours was not significantly different from
patients with BCAR4-negative/ERBB2-low tumours. Patients with
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Figure 3 Lapatinib treatment inhibits ERBB2 and ERBB3 signalling in ZR/BCAR4 cells. (A) Molecular network analysis of ZR-75-1-derived antioestrogen-
resistant cell lines (horizontal axis) treated with lapatinib. Lysates were analysed with reverse-phase protein microarrays. The heatmap presents the different
total and phosphorylated proteins (n¼ 31; vertical axis) that showed at least two-fold difference with the vector control cultured in the presence of
oestradiol (colour version in Supplementary Figure 1 and protein data in Supplementary Table 1). Higher relative levels are represented in white; lower levels
in black. Cells were cultured with oestradiol (E) or 4-hydroxytamoxifen (T), or T and EGF (Tþ ) and treated for 17 h, without, or with 0.01 or 0.1mM
lapatinib (triangles represent increasing lapatinib concentrations, from left to right). (B–H) Effects of lapatinib treatment on ERBB2 and ERBB3 signalling.
Phosphorylation intensity (Y axis) of ERBB2 (B), ERBB3 (C), AKT (D), FAK (E), SHC (F), STAT5 (G), and STAT6 (H) in the different cell lines (horizontal
axis) is presented. Results of two independently derived pools of transduced cells were averaged. Phosphorylation intensity values for antibody staining were
negative control subtracted and normalised for total protein concentration. An average of three measurements is presented. SD values o2% across the
replicates, the three bars for each cell line represent the three different conditions (no or 0.01 or 0.1 mM lapatinib).
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BCAR4-positive/ERBB2-high tumours had the shortest MFS
(multivariate HR¼ 1.95, P¼ 0.026; Supplementary Table 4). Ana-
lysis for OS indicated that patients with BCAR4-positive/ERBB2-
low tumours had a significantly shorter OS than patients with
BCAR4-negative/ERBB2-low tumours. This difference was inde-
pendent of the traditional prognostic factors (multivariate
HR¼ 1.54, P¼ 0.021). Patients with BCAR4-positive/ERBB2-high
tumours had the shortest OS from all groups (multivariate
HR¼ 2.25, P¼ 0.004; Supplementary Table 4).
DISCUSSION
In this study we show that BCAR4 expression sensitises two breast
cancer models to lapatinib. As BCAR4 expression in cell lines did
not change the sensitivity to different chemotherapeutic agents, the
increased sensitivity to lapatinib is not due to a general mechanism
of drug resistance. The combination of lapatinib and tamoxifen
treatment is more effective at inhibiting breast cancer cell growth
than lapatinib alone (Chu et al, 2005; Leary et al, 2010). Also in our
BCAR4-expressing cell models, the combination of lapatinib and
antioestrogens was more potent in inhibiting cell growth than
lapatinib alone; indicating that blocking the ERBB2 pathway with
lapatinib re-sensitises BCAR4-expressing cells to antioestrogens.
Breast tumours have been shown to alternate between ER and
ERBB2 signalling, and inhibition of one of the pathways
reactivated the other (Gutierrez et al, 2005; Lipton et al, 2005;
Massarweh and Schiff, 2006; Munzone et al, 2006; Creighton et al,
2008). It has also has been reported that increased ER signalling
occurs in lapatinib-treated breast cancer cell lines (Xia et al, 2006;
Leary et al, 2010). In the presence of lapatinib and increasing levels
of oestradiol, ZR/BCAR4 cells exhibited comparable cell growth
kinetics as oestrogen-dependent parental cells (Figure 5A). In
culture medium containing lapatinib without oestradiol growth of
ZR/BCAR4 cells was strongly inhibited. This suggests that BCAR4
cells use the ER signalling pathway to survive in the presence of
low concentrations of lapatinib. Likewise, MCF7/BCAR4 cells
cultured in medium without antioestrogens use the ER pathway to
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Figure 4 Lapatinib-treated cells utilise ER signalling for survival. ZR/
BCAR4 (A) and ZR/vector (B) cells were plated in the absence (K),
0.01mM lapatinib (J), 0.1 (’), or 1mM (&) of lapatinib and different
concentrations of oestradiol, as indicated. Results are expressed as a
percentage of maximal growth (cultures with 1 nM oestradiol but without
lapatinib), as measured with a WST-1 proliferation assay. Average of three
replicates and SD values are presented.
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Figure 5 Clinical relevance of combined BCAR4 and ERBB2 status.
Expression of BCAR4 and ERBB2 mRNA levels was measured in a cohort of
primary breast carcinomas. Patients were stratified according to the
combined BCAR4 and ERBB2 status as indicated. BCAR4 was divided in
negative (no call), and positive low and high by the mean. There is no
relation observed between BCAR4 and ERBB2 expression. (A) Prevalence
of breast tumours expressing BCAR4 and low levels of ERBB2. Number of
tumours and percentages are shown for each group. (B) Progression-free
survival of patients with ER-positive breast cancer who received first-line
tamoxifen monotherapy for recurrent breast cancer. Patients with ERBB2-
high tumours were grouped irrespective of their BCAR4 status. The
patients at-risk at 12-month intervals are indicated. Abbreviations:
neg¼ negative, pos¼ positive.
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proliferate. These cells are antioestrogen-resistant, but similar to
ZR/BCAR4 cells, proliferation is reduced when ERBB2 or ERBB3
are knocked-down. This indicates that MCF7/BCAR4 cells are also
dependent on the ERBB2 and ERBB3 pathway to overcome the
inhibitory effects of antioestrogens. Apparently, BCAR4 expression
enables cells to alternate between signalling pathways to escape the
inhibition of one of them.
The mechanism by which BCAR4 activates the ERBB2 and
ERBB3 receptors is still unknown, but several hypotheses can be
considered. BCAR4 may encode a very small protein, and its
predicted anchor signal and two transmembrane domains suggest
that the protein is located at cell membranes. Because of its
possible location and interaction with ERBB receptors, there is a
possibility that BCAR4 may be a target for ADAM proteins, which
cleave ERBB ligands (Mochizuki, 2007). This way, cleaved BCAR4
would be free to bind ERBB3, activating ERBB2 and ERBB3
signalling. BCAR4 may interact with ERBB2 through the cell
membrane, similar to MUC4 (Carraway et al, 2001). A mechanism
similar to nucleolin, which interacts intracellular and activates the
ERBB receptors (Di Segni et al, 2008). The hypothesis that BCAR4
may be a secreted protein can also not be excluded. Another
possibility is that the BCAR4 protein interacts with and stabilises
the ERBB2/ERBB3 dimer, or interferes with the internalisation
and/or intracellular transport of the receptors. It has been shown
that mucins can influence receptor trafficking and localisation, and
because of that, can modulate receptor tyrosine kinase signalling
(Funes et al, 2006).
Lapatinib treatment has been shown to prevent ubiquitination
and degradation of ERBB2, resulting in the accumulation of
inactive receptors at the plasma membrane (Scaltriti et al, 2009).
Exposure of ZR/BCAR4 cells to lapatinib resulted in modestly
increased ERBB2 protein levels. Addition of 4-hydroxytamoxifen
to ZR/BCAR4 cells further increased ERBB2 levels, in agreement
with earlier observations (Van Agthoven et al, 1994; Bates and
Hurst, 1997). In other studies, lapatinib was shown to inhibit
phosphorylation of ERBB2 downstream kinases in ERBB2-over-
expressing breast cancer (Xia et al, 2002, 2004; Chu et al, 2005;
Spector et al, 2005; Konecny et al, 2006). In our model, activity of
ERBB2, ERBB3, and the downstream mediators studied are efficiently
inhibited in medium containing oestradiol and a low dose of lapatinib.
However, cell proliferation was only partially inhibited, again
suggesting an escape route via the ER signalling pathway.
EGFR and ERBB2 overexpression is well documented as being
involved in tamoxifen resistance (Riggins et al, 2007; Musgrove
and Sutherland, 2009; Van Agthoven et al, 2009). EGFR is not
involved in our cell models of endocrine resistance because
oestrogen-dependent ZR-75-1 and MCF7 cells are devoid of
detectable EGFR expression (Van Agthoven et al, 1992), and
ERBB2 is present but not overexpressed nor amplified (Hollestelle
et al, 2010). Introduction of BCAR4 activates ERBB2 signalling and
induces resistance against antioestrogens (Van Agthoven et al,
2012). This suggests that not only ERBB2 overexpression or
amplification is associated with tamoxifen resistance, but that the
mere activation of the receptor may also have a role in the process.
This is in agreement with earlier findings that other models of
endocrine resistance, LTED and LTAM cells, showed increased
activation of ERBB2 and downstream signalling (Leary et al, 2010).
In addition, it has been hypothesised that moderate, as well as low
ERBB2 levels, may generate a strong mitogenic signal when the
receptor is activated by dimerisation with EGFR or ERBB3 (Frogne
et al, 2009).
In ZR/BCAR4 cells cultured with 4-hydroxytamoxifen, the IC50
for lapatinib was approximately 1 mM. This concentration is
achieved in the plasma of patients treated with the recommended
daily dose of 1.5mg (Burris et al, 2005), emphasising the potential
feasibility of lapatinib as treatment for antioestrogen resistant
breast cancer due to BCAR4 expression. Activated ERBB2 has been
found in ER-positive tumours classified as negative for ERBB2
expression according to the standard criteria (Frogne et al, 2009).
Moreover, emerging evidence shows that some tumours scoring
negative for ERBB2 expression benefit from trastuzumab therapy
(Paik et al, 2008; Esteva et al, 2010). At present, treatment with
ERBB2-targeted therapies is restricted to patients with breast
cancers overexpressing ERBB2. Until now, there are no biomarkers
to select patients with ER-positive/ERBB2-negative tumours, which
are dependent on ERBB2 signalling (Mayer and Arteaga, 2010),
and may benefit from ERBB2-targeted therapies. Although it has
been shown that the combination of lapatinib and an aromatase
inhibitor is not beneficial for ERBB2-negative, endocrine sensitive
or endocrine naive metastatic breast cancer patients (Johnston
et al, 2009), this remains to be established for BCAR4-positive
tumours.
We have shown that co-expression of BCAR4 and low level of
ERBB2 occurs frequently, and that these patients have less benefit
from tamoxifen treatment. Although our observations do not
prove that the ERBB2 signalling pathway is activated in these
tumours, our experimental data suggest that this group might
benefit from the combination of lapatinib and antioestrogens. The
focus of our future studies will be to determine the phosphoryla-
tion status of ERBB2 and downstream mediators on micro tissue
Table 1 Associations of combined mRNA levels of BCAR4 and ERBB2 in primary breast tumours with progression-free survival
Univariate analysis Multivariate analysis
PFS No. HR 95% CI P HR 95% CI P
ERBB2
High vs low 37/256 1.86 1.31–2.65 0.001 1.90 1.28–2.80 0.001
BCAR4
Pos vs neg 78/215 1.57 1.20–2.05 0.001 1.46 1.10–1.93 0.009
Combined addition
BCAR4 neg/ERBB2 low 191 1 1
BCAR4 pos/ERBB2 low 65 1.64 1.23–2.20 0.001 1.50 1.10–2.04 0.011
BCAR4 neg/ERBB2 high 24 2.17 1.40–3.36 0.001 2.09 1.32–3.29 0.002
BCAR4 pos/ERBB2 high 13 2.03 1.15–3.58 0.014 2.02 1.09–3.73 0.026
Abbreviations: PFS¼ progression-free survival; HR¼ hazard ratio; CI¼ confidence interval; pos¼ positive; neg¼ negative. To study a possible independent relationship of the
genes studied with PFS, Cox multivariate regression analyses were performed, including the base model comprising the traditional predictive factors: age, menopausal status,
disease-free interval, dominant site of relapse, and ESR1 and PGR mRNA levels. Clinicopathological and biological factors of ERa-positive metastatic breast cancers are presented
in Supplementary Table 5.
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arrays of a large cohort of breast cancers with known follow-up.
Patients with primary tumours with high levels of ERBB2 had the
shortest PFS, irrespective of their BCAR4 levels. On the basis of our
results it will now be highly relevant to establish whether these
BCAR4-positive/ERBB2-low cancers have indeed an activated
ERBB2 signalling pathway.
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